Clinical Trials
Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension
Bellerophon Therapeutics, Inc , a clinical-stage biotherapeutics company, announced the successful completion of its End-of-Phase 2 Meetings with the U.S. FDA for INOpulse for the...
Clinical Trials
Clinerion and iClusion partner to boost the identification and recruitment of more patients into clinical trials
Clinerion’s Patient Network Explorer and iClusion’s Trial Eye platforms both connect clinical trial sponsors with networks of partner hospitals, giving trial managers the ability to...
Clinical Trials
Biocair to participate in cell and gene webinar to explore ongoing material sourcing challenges
Christopher Good, Director of Cell and Gene Therapy Logistics at Biocair, will explore ongoing material sourcing challenges for organisations moving from development to clinical and...
Clinical Trials
Clinerion partners with Wefight to optimize patient recruitment in clinical trials by leveraging artificial intelligence to identify eligible patients from Vik community
Clinerion’s Patient Network Explorer platform allows clinical trial sponsors to identify cohorts of patients eligible for recruitment from its global network of partner hospitals. Wefight’s...
Clinical Trials
Rare Disease Patient Platform Raremark Partners With TriNetX
TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE), announced that Raremark, a patient-data...
Clinical Trials
IQVIA Launches Avacare Clinical Research Network to Increase Patients Clinical and Research Options
IQVIA™ (NYSE: IQV), a leader in human data science, announced the launch of Avacare Clinical Research Network™, a technology-based global site network that opens opportunities...
Clinical Trials
CytoDyn Receives IRB Approval to Initiate Phase 2 Basket Trial for 22 Solid Tumor Cancers
CytoDyn Inc , a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, reported that it has...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.